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Case Presentation cont’d

Background
• Mitomycin C (MMC) is a powerful DNA-alkylating
chemotherapeutic agent used to treat solid tumors (1) and
is a potent vesicant.
• Vesicants are a category of chemotherapeutic agents that
can cause tissue necrosis and blistering.
• MMC extravasation presents with a wide range of
cutaneous manifestations, such as mild rash to fulminant
tissue necrosis (2,3)

Case Presentation
• The patient is a 70-year-old woman with a past medical
history of hypertension and anal cancer
• The patient had a totally implantable venous access
device (port) placed for chemotherapy infusions. At the
start of the infusion, she experienced sudden pain and
burning tracking along the subcutaneous tissue of the
right shoulder, neck, and chest.
• The infusion was stopped, and she had the port
evaluated by interventional radiology. The port was found
to be intact, without any signs of leakage or
extravasation.
• She presented to the hospital a week later due to
worsening redness, pain, and skin changes. (Figure 1)
• Vitals and laboratory analysis were unremarkable upon
presentation.
• Computed tomography (CT) of the chest showed
inflammation of soft tissues overlying the right breast,
and a partially flipped port, lying at an oblique angle
(Figure 2).
• The patient was admitted to closely monitor for possible
progression to tissue necrosis. She underwent port
removal on hospital day 3. Tissue debridement was not
needed.
• The patient had a peripherally inserted central catheter
placed for her remaining chemotherapy infusions. Patient
was discharged on postoperative day 1 (hospital day 4).

Figure 1. Gross examination shows (A) extensive erythema of the right
chest wall surrounding the port site with (B) superficial ulceration and
blistering noted at superior-lateral chest wall.

Discussion
• DNA binding vesicants, like MMC, have the most
severe risk profile of the intravenous chemotherapies as
they can cause irreversible disability and disfigurement
due to tissue necrosis (3).
• Extravasation is multi-factorial adverse risk event
• Patient related risk factors include age, vein fragility,
lymphedema, and obese body habitus.
• Prolonged duration and increase rate, volume, and
concentration of the drug all increase the risk of
extravasation (4).
• Though central venous access devices reduce the risk
of extravasation, there is still a reported risk of 0.26% to
0.47% due to malposition, thrombosis, fragmentation, or
migration (5).
• The extravasation in our patient was presumed to be
secondary to a misplaced needle due to the suboptimal
port position.

Conclusion
• Prompt detection of extravasation is crucial in preventing
extensive tissue damage.
• As the inflammatory response mounts, the cutaneous
symptoms may appear similar to cellulitis or erysipelas.
• Patients receiving chemotherapy are at a higher risk of
developing multi-drug resistant infections.
• Therefore, it is imperative that clinicians practice excellent
antibiotic stewardship by correctly identifying the underlying
etiology in order to initiate the proper treatment
• Definitive treatment may require debridement of necrotic
tissue.
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Figure 2. Axial view of the CT scan of the chest showing (A) inflammation
of the soft tissue underlying the right breast and chest wall (red arrow) and
(B) the port lying obliquely under the skin (yellow arrow).
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